American Association for Cancer Research
Browse
mct-22-0004_supplementary_data_raw_s2_suppsd2.xlsx (6.23 MB)

Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Download (6.23 MB)
dataset
posted on 2023-04-03, 19:03 authored by Marta Llaurado Fernandez, E. Marielle Hijmans, Annemiek M.C. Gennissen, Nelson K.Y. Wong, Shang Li, G. Bea A. Wisman, Aleksandra Hamilton, Joshua Hoenisch, Amy Dawson, Cheng-Han Lee, Madison Bittner, Hannah Kim, Gabriel E. DiMattia, Christianne A.R. Lok, Cor Lieftink, Roderick L. Beijersbergen, Steven de Jong, Mark S. Carey, René Bernards, Katrien Berns
Supplementary Data from NOTCH Signaling Limits the Response of Low-Grade Serous Ovarian Cancers to MEK Inhibition

Funding

Oncode Institute

Ovarian Cancer Canada (OCC)

Chinese Scholarship Council

Women's Health Research Institute

Cure Our Ovarian Cancer

Janet D. Cottrelle Foundation (JDCF)

BC Cancer Foundation

VGH and UBC Hospital Foundation (VGH & UBC Hospital Foundation)

History

ARTICLE ABSTRACT

Low-grade serous ovarian cancer (LGSOC) is a rare subtype of epithelial ovarian cancer with high fatality rates in advanced stages due to its chemoresistant properties. LGSOC is characterized by activation of MAPK signaling, and recent clinical trials indicate that the MEK inhibitor (MEKi) trametinib may be a good treatment option for a subset of patients. Understanding MEKi-resistance mechanisms and subsequent identification of rational drug combinations to suppress resistance may greatly improve LGSOC treatment strategies. Both gain-of-function and loss-of-function CRISPR-Cas9 genome-wide libraries were used to screen LGSOC cell lines to identify genes that modulate the response to MEKi. Overexpression of MAML2 and loss of MAP3K1 were identified, both leading to overexpression of the NOTCH target HES1, which has a causal role in this process as its knockdown reversed MEKi resistance. Interestingly, increased HES1 expression was also observed in selected spontaneous trametinib-resistant clones, next to activating MAP2K1 (MEK1) mutations. Subsequent trametinib synthetic lethality screens identified SHOC2 downregulation as being synthetic lethal with MEKis. Targeting SHOC2 with pan-RAF inhibitors (pan-RAFis) in combination with MEKi was effective in parental LGSOC cell lines, in MEKi-resistant derivatives, in primary ascites cultures from patients with LGSOC, and in LGSOC (cell line–derived and patient-derived) xenograft mouse models. We found that the combination of pan-RAFi with MEKi downregulated HES1 levels in trametinib-resistant cells, providing an explanation for the synergy that was observed. Combining MEKis with pan-RAFis may provide a promising treatment strategy for patients with LGSOC, which warrants further clinical validation.

Usage metrics

    Molecular Cancer Therapeutics

    Categories

    Keywords

    Licence

    Exports